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Ultrasonographya b s t r a c t
Background: Variceal bleeding (VB), the most common lethal complication of cirrhosis, associated with
high mortality. Timely prediction of esophageal varices (EV) represents a real challenge for the medical
team. This study evaluated the level of plasma soluble CD 163 as a marker of the presence of EVs and to
compare it with other noninvasive clinical, laboratory and ultrasonographic parameters as well as endo-
scopy.
Methods: This prospective controlled study was conducted on 80 adults. Gp I had no oesophageal varices,
gp II had small varices, gp IIIa had large varices, gp IIIb are the same patients of gp IIIa but after eradica-
tion of varices and gp IV as healthy controls. Serum samples were assayed for soluble CD 163.
Results: soluble CD163 was statistically significant different between controls and all liver cirrhosis. it
showed a statistically significant difference between group I and II (p = 0.009) and between group I
and IIIa (p < 0.001) and between group II and IIIa (p < 0.001) but, no difference between group IIIa and
IIIb (p = 0.179).
Conclusion: Serum soluble CD163 is a good noninvasive predictor for the presence of EVs and it may be
used for grading of EVs. Its level does not change after esophageal varices eradication.
Trial registration: IRB No: 00007589 FWA No: 00015712 The Ethics Committee of the faculty of medicine
Alexandria University.
 2017 Alexandria University Faculty of Medicine. Production and hosting by Elsevier B.V. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Background
Cirrhosis is the end stage of every chronic liver disease,
resulting in formation of fibrous tissue, dis-organization of liver
architecture, and nodule formation, which interferes with liver
function and results in portal hypertension. Portal hypertension
is associated with development of a hyperdynamic circulation
and complications such as ascites, hepatic encephalopathy, and
oesophago-gastric varices.1 Oesophago-gastric varices are the most
relevant porto-systemic collaterals because their rupture results in
variceal bleeding (VB), the most common lethal complication of
cirrhosis, associated with a mortality of at least 20% at 6 weeks.2
Timely prediction of esophageal varices (EV) represents a real
challenge for the medical team. Nowadays, complete diagnosis ofportal hypertension (PHT) requires measurement of the porto-
systemic gradient, the parameter that gives the most accurate
information about the development of (EV). Although it is safe
but it still remains an invasive procedure.3 The gold standard
examination to establish the diagnosis of (EV) is endoscopy but,
the available method in rural areas is laboratory examination and
ultrasonography. Several studies have been performed to identify
predictive factors for esophageal varices.5
Current guidelines, recommend that all cirrhotic patients
should be screened for varices at diagnosis, with follow up every
2–3 years for patients without varices and 1–2 years for patients
with small varices. This guideline causes a significant burden and
cost to endoscopy units.4 The cost and invasive nature of endo-
scopic screening mean that there is interest in developing noninva-
sive predictors for EV.5 Noninvasive predictive variables as platelet
count, splenomegaly, Child Pugh, size of right liver lobe, albumin
level and portal vein diameter are based on regular laboratory
parameters and clinical signs relevant fibrosis, portal hypertension
and hypersplenism.6
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toglobin scavenger receptor and a specific marker for macrophage
activation.7,8 CD (163) is shed into the circulation in a soluble form
sCD (163) after Toll-like receptor activation by a similar mecha-
nism as TNF-a.9 Serum concentrations of sCD (163) are accordingly
elevated during conditions of macrophage activation and prolifer-
ation.10 Elevated circulating sCD (163) has been demonstrated in
viral hepatitis, acute liver failure and cirrhosis.11–13 Hepatic kupffer
cells are activated in cirrhotic patients in parallel with their portal
hypertension. sCD (163) is a sensitive marker of macrophages acti-
vation that positively correlated with the degree of portal hyper-
tension in cirrhotic patients.14 In a recent study of highly
selected cirrhotic patients setup for treatment with transjugular
intrahepatic porto-systemic shunt (TIPS), sCD163 was released
from the liver, confirming the activation of Kupffer cells, and its
level rose with the portal pressure.14 This study evaluated the level
of plasma soluble CD 163 as a marker of the presence of esophageal
varices (EVs) in cirrhotic patients and to compare it with other
noninvasive clinical, laboratory and ultrasonographic parameters
as well as upper gastrointestinal endoscopic findings.2. Methods
After ethical approval for this clinical trial from the local com-
mittee of ethics in the faculty of medicine of Alexandria university
and the department of tropical medicine, Informed consent was
taken from healthy volunteers and the next of kin. This prospective
controlled study was conducted on 80 adult subjects (n = 80), they
were divided into 5 groups. Group I Contains 20 patients with liver
cirrhosis without oesophageal varices. Group II contains 20
patients with liver cirrhosis with small oesophageal varices grade
(I, II). Group IIIa contains 20 patients with liver cirrhosis with large
oesophageal varices grade (III, IV). Group IIIb are the same 20
patients of group IIIa but after eradication of oesophageal varices.
Group IV contains 20 healthy subjects as normal controls.
We classified all patients using upper endoscopy and The
varices was classified according to Comar and Sanyal into small
or large oesophageal varices. Also, portal hypertensive gastropathy
was graded according to McCormack’s classification into no, mild
(snake skin appearance) and severe (submucosal hemorrhagic
spots). Eradication of oesophageal varices was done for group IIIa
patients by endoscopic variceal band ligation immediately at time
of diagnosis and then other sessions 3 weeks, 6 weeks and 8 weeks
later on (one or more sessions was needed with one-month inter-
val until eradication of oesophageal varices was achieved), Banding
was done by capturing the targeted varix till complete red out
occurs.
We considered all hepatic patients admitted for enrollment in
this study but we excluded patients on b-blockers or nitrates or
any other pharmacological agents which reduce portal hyperten-
sion, patients with hepatocellular carcinoma or acute liver failure,
patients with any infectious or inflammatory diseases (such as sep-
sis, tuberculosis, Rheumatoid arthritis etc.) and patients with dia-
betes mellitus, hypertension or renal impairment or other
comorbid conditionswhich hinder doing the endoscopic procedure.
All enrolled persons included in this study were subjected to
complete history taking including demographic data and clinical
data such as abdominal distension, dyspepsia, jaundice, bleeding
tendency, weight loss, anemia manifestation, hematemesis and
melena. They were clinically examined for liver, spleen, detection
of ascites and manifestations of hepatocellular failure. They were
subjected to laboratory investigations as complete blood picture
(CBC), prothrombin time (PT) and activity, Serum alanine amino-
transferase (ALT), Serum aspartate aminotransferase (AST), Serum
alkaline phosphatase (ALP), Total and direct serum bilirubin, Bloodurea nitrogen (BUN), Serum Creatinine, fasting blood glucose and
fasting insulin level. Insulin resistance index ‘‘HOMA IR” was calcu-
lated as ‘‘Blood glucose level mg/dl  insulin/405”.
Serum samples from all persons were assayed for our main
study marker ‘‘Soluble CD 163”. Also, it was evaluated at time of
eradicated varices for patients of group IIIb. We calculated Child
Pugh score and classified all participating patients according to
presence of hepatitis C virus antibodies (ELISA), hepatitis B surface
antigen (ELISA) and Antischistosomal antibodies (IHAT).
Regarding ultrasonic parameters, we evaluated all enrolled
patients using ultrasound assessment of liver and ascites to detect
the presence of cirrhosis and/or bilharsial hepatic fibrosis. They
were assessed using ultrasound measurement of right liver lobe
diameter, splenic bipolar diameter and ultrasound Doppler mea-
surement of the portal vein. We considered all noninvasive clinical,
laboratory parameters and predictive Scores such as AST to plate-
lets ratio index(APRI)15 calculated as [(AST/ULN)  100]/platelet
count 109/L (ULN = the upper limit of normal), Index for liver fibro-
sis FIB416 calculated as [age (years)  AST (IU/L)]/[platelet count
(109/L)  ALT (IU/L)1/2], Lok score17 calculated as log
odds = 5.56  0.0089  platelet count(103/mm3) + 1.26  (AST/
ALT) + 5.27  INR; Lok = [exp (log odds)]/[1 + exp(logodds)], Plate-
let Count 109/Spleen Diameter Ratio(mm), AST/ALT Ratio. and
Right Lobe Liver Diameter (cm)/Albumin Ratio.2.1. Statistical methods
Data entry and analysis were done using SPSS software v24.
Continuous values were described by mean and standard devia-
tion. Categorical values were described by counts and proportions.
Univariate analysis for determining the association of various clin-
ical and laboratory variables with the stage of liver fibrosis and the
presence or absence of EV was performed using Student’s t-test for
continuous variables and v2 test for categorical variables. Differ-
ences were considered statistically significant if p-value was less
than 0.05. To determine the clinical utility and the diagnostic per-
formance of markers, 2 receiver operating characteristic (ROC)
curves were constructed for each of the non-invasive scoring sys-
tems that appeared significant in the univariate analysis. Perfor-
mance of the non-invasive markers was expressed as sensitivity,
specificity, positive and negative predictive values (PPV and NPV)
and test accuracy.3. Results
Regarding the demographic data of the studied groups, there
were no any significant differences between the studied groups
in age and sex. Males predominated females (55% in group I, 60%
in group II, 85% in group III and 60% in control group|), while the
mean age was 52.0 years, 54.45 years, 52.55 years and 50.59 years
in group I, II, III and control group respectively. There was no any
significant difference between the studied groups as regard body
mass index (BMI) (Table 1).
Regarding symptoms of patients at admission, the most com-
mon symptoms in group (I) was abdominal distension (55%) fol-
lowed by dyspepsia (40%) while jaundice and weight loss were
present in (30%) of patients. However, 80% of group II patients
complained of a dyspepsia, 75% suffered from abdominal disten-
sion and 65% of this group had bleeding tendency. In group IIIa,
90% had dyspepsia, 85% had anemia manifestations and 60% had
abdominal distention and bleeding tendency while melena was
present in 65% of this group.
Regarding the etiology of liver cirrhosis, Group I was mainly
HCV positive patients, only one patient with HBV and he was
enrolled in group IIIa, all patients in group II were HCV positive,
Table 1









Test of sig. p
No. % No. % No. % No. %
Sex
Female 9 45.0 8 40.0 3 15.0 8 40.0 v2 = 4.835 0.184*
Male 11 55.0 12 60.0 17 85.0 12 60.0
Age
Min.–Max. 35.0–73.0 46.0–71.0 45.0–65.0 40.0–61.0 F = 0.969 0.412*
Mean ± SD. 52.0 ± 7.89 54.45 ± 6.29 52.55 ± 5.29 50.95 ± 6.93
BMI (kg/m2)
Min.–Max 22.0–28.10 24.0–30.70 23.0–31.90 22.0–27.0 F = 2.287 0.085*
Mean ± SD. 26.01 ± 1.95 27.17 ± 2.30 27.40 ± 2.49 26.15 ± 1.42
v2: Chi square test, F: ANOVA test, p: p value for comparing between the four groups.
* Statistically significant at p  0.05.
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antibodies titer (Table 2). Regarding local abdominal examination
of liver, there was no a statistically significant difference between
groups I, II and IIIa in liver enlargement. But, there were significant
differences between them in spleen enlargement and clinically
detected ascites. (Table 3) The Child-Pugh score of all patients is
showed in (Table 4)
Regarding lab investigations, CBC results showed significant dif-
ferences between liver cirrhosis groups (I, II and IIIa) and control
group IV in all parameters. Within the liver cirrhosis groups, hemo-
globin level showed a statistically significant difference between
group I and IIIa (p2 < 0.001) and between group II and IIITable 2







No. % No. % No.
HCV anti bodies
Negative 1 5.0 0 0.0 2
Positive 19 95.0 20 100.0 18
HBS antigen
Negative 20 100.0 20 100.0 19
Positive 0 0.0 0 0.0 1
Schistosomal anti bodies titer
Negative 9 45.0 12 60.0 8
Positive 11 55.0 8 40.0 12
v2: Chi square test, MC: Monte Carlo for Chi square test, p: p value for comparing betw
* Statistically significant at p  0.05.
Table 3
Comparison between the three studied groups according to Local abdominal examination






Not enlarged 19 95.0 13
Enlarged 1 5.0 7
Spleen
Not enlarged 19 95.0 8
Enlarged 1 5.0 12
Clinically detected ascites
Absent 16 80.0 6
Present 4 20.0 14
v2: Chi square test, MC: Monte Carlo for Chi square test, p value.
* Statistically significant at p  0.05.(p3 < 0.001) but no significant difference was found between group
I and II (p1 = 0.960). Platelets count showed statistically significant
differences between group I and II (p1 = 0.037) and between group
I and III (p2=0.003) but no significant difference was found
between group II and III (p3 = 0.797). There was a significant differ-
ence between group I, II and IIIa in comparison to control as regard
fasting insulin level (p < 0.001) and HOMA IR (p < 0.001) with no
statistically significant difference in fasting blood glucose level
(p = 0.924). While HOMA IR showed a statistically significant dif-
ference between group I and III (p2 = 0.003) only. (Table 5) All








10.0 20 100.0 66.575 <0.001*
90.0 0 0.0
95.0 20 100.0 2.842 MCp =
1.0005.0 0 0.0
40.0 20 100 80.0 <0.001*
60.0 0 0.0






65.0 14 70.0 6.204 MCp = 0.062
35.0 6 30.0
40.0 0 0.0 36.768* <0.001*
60.0 20 100.0
30.0 5 25.0 14.949* 0.001*
70.0 15 75.0
Table 4







Test of sig. p
No. % No. % No. %
Classes
A 11 55.0 0 0.0 2 10.0 v2 = 27.972* MCp
< 0.001*B 7 35.0 17 85.0 7 35.0
C 2 10.0 3 15.0 11 55.0
Scores
Mean ± SD. 6.70 ± 2.0 8.60 ± 1.54 9.60 ± 2.26 F = 11.358 <0.001*
Sig. bet. grps p1 = 0.003*, p2 < 0.001*, p3 = 0.111
v2: Chi square test, MC: Monte Carlo for Chi square test, F: ANOVA test, Sig. bet. grps was done using test (LSD) for ANOVA.
p: p value for comparing between the three groups.
p1: p value for comparing between group I and group II.
p2: p value for comparing between group I and group III.
p3: p value for comparing between group II and group III.
* Statistically significant at p  0.05.
Table 5
Comparison between the different studied groups according to lab investigations.
Group I Group II (n = 20) Group IIIa (n = 20) IV Control (n = 20) Test of Sig. p
HB(g/dl)
Mean ± SD. 12.06 ± 1.91 11.83 ± 1.63 9.57 ± 1.17 14.27 ± 1.03 F = 33.714* <0.001*
pCont. <0.001* <0.001* <0.001*
Sig. bet. grps p1 = 0.960, p2 < 0.001*,p3 < 0.001*
RBCs
Mean ± SD. 3.96 ± 0.82 4.14 ± 0.71 3.45 ± 0.67 4.31 ± 0.39 F = 6.228* 0.001*
pCont. 0.350 0.846 0.001*
Sig. bet. grps p1 = 0.831, p2 = 0.082, p3 = 0.009*
WBCs
Mean ± SD. 5.14 ± 1.68 5.21 ± 1.81 4.45 ± 1.55 7.43 ± 1.78 H = 24.813* <0.001*
pCont. <0.001* <0.001* <0.001*
Sig. bet. grps p1 = 0.860, p2 = 0.140, p3 = 0.074
Platelets
Mean ± SD. 135.10 ± 53.74 97.30 ± 48.65 89.25 ± 33.57 327.85 ± 70.72 H = 48.823 <0.001*
pCont. <0.001* <0.001* <0.001*
Sig. bet. grps p1 = 0.037*, p2 = 0.003*, p3 = 0.797
Fasting insulin level
Mean ± SD. 11.63 ± 2.12 18.14 ± 1.55 22.92 ± 3.72 7.94 ± 2.10 F = 141.752 <0.001*
pCont. <0.001* <0.001* <0.001*
Sig. bet. grps p1 < 0.001*,p2 < 0.001*, p3 < 0.001*
FBS g/dl
Mean ± SD. 88.37 ± 13.73 89.27 ± 11.46 91.12 ± 13.40 90.27 ± 14.84 F = 0.159 0.924
HOMA IR
Mean ± SD. 2.49 ± 0.37 3.03 ± 0.81 3.64 ± 1.20 1.82 ± 0.70 17.636 <0.001*
pCont. 0.059 <0.001* <0.001*
Sig. bet. grps p1 = 0.173,p2 < 0.001*,p3 = 0.098
F: ANOVA test, Sig. bet. grps was done using test (Tukey) for ANOVA.
H: Kruskal Wallis test, Sig. bet. grps was done using Mann Whitney test.
p: p value for comparing between the four groups.
pCont.: p value for comparing between control and each other periods.
p1: p value for comparing between group I and group II.
p2: p value for comparing between group I and group III.
p3: p value for comparing between group II and group III.
* Statistically significant at p  0.05.
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ences between each group of patients and group IV of controls in
all parameters (p < 0.001). The mean of Serum aspartate amino-
transferase (AST) of group I was higher than group II with a statis-
tically significant difference (p1 = 0.010). The mean of serum
albumin level showed significant differences between all groups.
(Table 6) The results of coagulation profiles of all groups are
showed in (Table 7).
Regarding ultrasonography, all subjects were cirrhotic except in
control group and 60% of subjects in group I and 40% of subjects ingroup II and IIIa group showed mixed cirrhosis with Schistosomal
periportal hepatic fibrosis. Within group I, II and IIIa ascites was
not present in 80% of subjects of group I while it was found as mild
ascites in 50% of patients of group II and moderate ascites in 35% of
patients of group IIIa. Direction of portal bloodflowwas hepatopetal
in 100% of subjects in control and group I while it was non hep-
atopetal (hepatofugal) in 50% and 65% of subjects of group II and
III respectively. Significant difference was found as regard portal
blood volume between control group and liver cirrhosis group with
median 1241.0 in group of controls. Moreover, within liver cirrhosis
Table 6
Comparison between the different studied groups according to liver profiles.








Test of sig. p
ALT(U/L) H = 27.516 <0.001*
Mean ± SD. 55.95 ± 21.48 53.55 ± 26.35 44.20 ± 25.53 26.50 ± 7.58
pCont. <0.001* <0.001* 0.001*
Sig. bet. grps p1 = 0.379,p2 = 0.025*,p3 = 0.099
AST(U/L) H = 30.470 <0.001*
Mean ± SD. 47.70 ± 23.04 71.45 ± 43.32 58.60 ± 32.77 29.75 ± 7.68
pCont. 0.001* <0.001* <0.001*
Sig. bet. grps p1 = 0.010*,p2 = 0.343, p3 = 0.168
Albumin (g/dl) F = 39.465 <0.001*
Mean ± SD. 3.30 ± 0.52 2.67 ± 0.41 2.47 ± 0.78 4.12 ± 0.26
pCont. <0.001* 0.627 <0.001*
Sig. bet. grps p1 = 0.002*,p2 < 0.001*,p3 = 0.002*
Total bilirubin (mg/dl) H = 24.375 <0.001*
Mean ± SD. 1.63 ± 0.80 1.82 ± 0.99 2.58 ± 1.56 0.93 ± 0.12
pCont. 0.005* <0.001* <0.001*
Sig. bet. grps p1 = 0.440,p2 = 0.032*, p3 = 0.129
Direct bilirubin (mg/dl) H = 33.656 <0.001*
Mean ± SD. 0.68 ± 0.42 0.91 ± 0.58 1.29 ± 1.16 0.19 ± 0.05
pCont. <0.001* <0.001* <0.001*
Sig. bet. grps p1 = 0.328,p2 = 0.131, p3 = 0.684
Alkaline phosphatase (u/l) 25.261 <0.001*
Mean ± SD. 146.20 ± 34.68 141.06 ± 27.31 157.93 ± 38.23 81.60 ± 16.75
pCont. <0.001* <0.001* <0.001*
Sig. bet. grps p1 = 0.950,p2 = 0.616, p3 = 0.303
F: ANOVA test, Sig. bet. grps was done using test (Tukey) for ANOVA.
H: Kruskal Wallis test, Sig. bet. grps was done using Mann Whitney test.
p: p value for comparing between the four groups.
pCont.: p value for comparing between control and each other periods.
p1: p value for comparing between group I and group II.
p2: p value for comparing between group I and group III.
p3: p value for comparing between group II and group III.
* Statistically significant at p  0.05.
Table 7










Activity (%) 45.312* <0.001*
Mean ± SD. 69.13 ± 15.69 52.62 ± 9.10 59.64 ± 14.97 93.94 ± 4.72
pCont. <0.001* <0.001* <0.001*
Sig. bet. grps p1 < 0.001*,p2 = 0.068, p3 = 0.258
Time (sec.) 10.423* <0.001*
Mean ± SD. 14.91 ± 3.27 17.42 ± 6.69 16.0 ± 2.84 10.60 ± 1.67
pCont. 0.007* 0.689 <0.001*
Sig. bet. grps p1 = 0.216,p2 = 0.832, p4 = 0.216
INR 20.847* <0.001*
Mean ± SD. 1.46 ± 0.34 1.55 ± 0.19 1.65 ± 0.40 0.99 ± 0.14
pCont. <0.001* <0.001* <0.001*
Sig. bet. grps p1 = 0.736,p2 = 0.178, p3 = 0.733
F: ANOVA test, Sig. bet. grps was done using test (Tukey) for ANOVA, p: p value for comparing between the four groups.
pCont.: p value for comparing between control and each other periods.
p1: p value for comparing between group I and group II.
p2: p value for comparing between group I and group III.
p3: p value for comparing between group II and group III.
* Statistically significant at p  0.05.
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between group I and III but no significant difference was found
between group II and III. In terms of portal vein diameter, statisti-
cally significant differences were found between group I and III
(p2 < 0.001) and between group II and III (p3 < 0.001) but not
between group I and II (p1 = 0.549). (Table 8) (Appendix A)
Regarding the classic predictive scores, APRI was higher in
group II than group I with a statistically significant difference
(P < 0.001). FIB4 was higher in group II than group I with a statis-tically significant difference (P < 0.001). There was no significant
difference between group II and III in their lok score (p3 = 0.909).
AST/ALT Ratio and Right lobe liver diameter (cm)/albumin ratio
was evaluated also as predictive scores (Table 9).
All patients assigned to the groups using upper GI endoscopy
and during it, portal hypertensive gastropathy grading was done
and revealed that 55% of patients of group I had no PHG and 55%
of patients of group II had mild PHG while 35% of subjects of group
III had severe PHG. oesophageal variceal band ligation sessions
Table 8
Comparison between the studied groups according to ultra-sonographic data.
Ultra Sonographic data Group I (n = 20) Group II (n = 20) Group IIIa (n = 20) IV Control
(n = 20)
Test of sig. p
No. % No. % No. % No. %
No liver cirrhosis 0 0.0 0 0.0 0 0.0 20 100.0 v2= 80.0 <0.001*
Liver cirrhosis 20 100.0 20 100.0 20 100.0 0 0.0
No SHF 8 40.0 12 60.0 8 40.0 20 100.0 v2= 20.000 <0.001*
SHF 12 60.0 8 40.0 12 60.0 0 0.0
Ascites
No 16 80.0 6 30.0 6 30.0 20 100.0 v2= 38.546 MCp < 0.001*
Mild 4 20.0 10 50.0 6 30.0 0 0.0
Moderate 0 0.0 4 20.0 7 35.0 0 0.0
Tense 0.0 0 0 0.0 1 5.0 0 0.0
Direction of portal
blood flow
Hepatopetal 20 100.0 10 50.0 7 35.0 20 100.0 v2= 33.379 <0.001*
Non hepatopetal 0 0.0 10 50.0 13 65.0 0 0.0
Portal blood volume
Mean ± SD. 843.75 ± 182.40 672.65 ± 185.32 559.75 ± 97.75 1222.70 ± 66.75 F = 82.356 <0.001*
pCont. <0.001* <0.001* <0.001*
Sig. bet. grps p1 = 0.002*,p2 < 0.001*, p3 = 0.068
Liver right lobe
diameter(cm)
Mean ± SD. 13.56 ± 0.78 12.83 ± 0.84 10.87 ± 1.02 15.01 ± 0.82 F = 77.888 <0.001*
pCont. <0.001* <0.001* <0.001*
Sig. bet. grps p1 = 0.047*,p2 < 0.001*, p3 < 0.001*
Spleen bipolar
diameter (cm)
Mean ± SD. 13.84 ± 1.23 15.44 ± 1.37 19.59 ± 2.09 10.30 ± 1.29 F = 125.746 <0.001*
pCont. <0.001* <0.001* <0.001*
Sig. bet. grps p1 = 0.008*,p2 < 0.001*p3 < 0.001*
Portal vein
diameter (mm)
Mean ± SD. 12.71 ± 0.93 13.35 ± 1.90 16.38 ± 1.76 9.84 ± 1.34 F = 61.668 <0.001*
pCont. <0.001* <0.001* <0.001*
Sig. bet. grps p1 = 0.549, p2 < 0.001*p3 < 0.001*
F: ANOVA test, Sig. bet. grps was done using test (Tukey) for ANOVA.
v2: Chi square test.
p: p value for comparing between the four groups.
pCont.: p value for comparing between control and each other periods.
p1: p value for comparing between group I and group II.
p2: p value for comparing between group I and group III.
p3: p value for comparing between group II and group III.
* Statistically significant at p  0.05.
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IIIa with mean of 3.0 (±1.45) sessions and duration mean 6.50
(±3.0) weeks. (Appendix B)
Regarding our main study marker, ‘‘soluble CD163” was statis-
tically significant different between control and liver cirrhosis
groups with a mean 69.03 (ng/ml) in control and 151.52 (ng/ml),
183.75 (ng/ml) and 209.52 (ng/ml) in group I, II and IIIa respec-
tively. Moreover, within group I, II and IIIa it showed a statistically
significant difference between group I and II (p = 0.009) and
between group I and IIIa (p < 0.001) and between group II and IIIa
(p < 0.001). There was no difference between group IIIa and IIIb
(p = 0.179). (Fig. 1)
Regarding the presence of EV, serum soluble CD163 level,
HOMA and platelets count are good predictors for presence of
oesophageal varices with cut off value > 191.71 for soluble CD163
with 77.50% sensitivity and 77.0% specificity. Soluble CD163,
HOMA IR and Platelets to predict presence of EV between (Group
II + Group IIIa) vs Group I showed the best sensitivity and speci-
ficity 90% and 80% respectively and 90% PPV and 80% NPV.
(Fig. 2) APRI, FIB4, Lok score, platelets count to spleen diameter
ratio and AST/ALT ratio are good predictors. All new variables sen-
sitivity and specificity are showed in (Table 10). Moreover, ability
of the studied marker soluble CD163 to differentiate between small
varices and large varices with cut off value 199.19 with 85.0 % sen-
sitivity and 90.0% specificity. (Table 11), (Fig. 3)4. Discussion
Several non-invasive methods have emerged in recent years,
assessing the potential of various laboratory, clinical, and ultra-
sonographic parameters, linked directly or indirectly to portal
hypertension including: Thrombocytopenia, splenomegaly18. AST/
ALT ratio,19 AST to platelets ratio index (APRI).20 platelets count
to spleen diameter ratio,21 The right liver lobe diameter/albumin
index,22 Transient elastography,23 Forns Index,24 Lok score25 and
Insulin resistance.26
Insulin resistance which is firstly introduced by Cammà et al.
study, which stated that Insulin resistance measured by HOMA-
IR, regardless of the presence of diabetes, significantly predicts
the presence of EV26.Studies in chronic liver diseases have shown
a strong and independent pathogenic link between Insulin resis-
tance (IR) and HCV infection and between IR and the severity of
hepatic fibrosis.27 Cammà et al.26 studied 104 patients of Child A
HCV induced cirrhosis conclude that HOMA-IR score of greater
than 3.5 is the cut-off value with the best sensitivity 61% and speci-
ficity 76% for predicting EV presence and HOMA score less than 3.5
(if non-diabetic) could be useful to identify patients at low risk of
EV.26 Eslam et al.,28 also concluded that in patients with cirrhosis,
the presence of esophageal varices was independently associated
with lower platelet count and raised HOMA score with HOMA
score correlates with HVPG and independently predict clinical
Table 9









Test of Sig. p
AST to platelets ratio index (APRI) H = 50.971 <0.001*
Mean ± SD. 1.11 ± 0.72 2.47 ± 1.75 1.93 ± 0.92 0.24 ± 0.09
pCont. <0.001* <0.001* <0.001*
Sig. bet. grps p1 = 0.003*,p2 = 0.004*, p3 = 0.525
FIB4 H = 54.983 <0.001*
Mean ± SD. 2.77 ± 1.31 6.88 ± 4.04 5.49 ± 2.05 0.95 ± 0.33
pCont. <0.001* <0.001* <0.001*
Sig. bet. grps p1 < 0.001*,p2 < 0.001*,p3 = 0.482
Lok score F = 157.928 <0.001*
Mean ± SD. 0.78 ± 0.23 0.96 ± 0.04 0.93 ± 0.10 0.15 ± 0.08
pCont. <0.001* <0.001* <0.001*
Sig. bet. grps p1 < 0.001*,p2 = 0.002*,p3 = 0.909
Platelet count /spleen diameter (mm) ratio H = 54.992 <0.001*
Mean ± SD. 997.65 ± 436.48 647.03 ± 349.53 462.80 ± 181.91 3233.10 ± 838.74
pCont. <0.001* <0.001* <0.001*
Sig. bet. grps p1 = 0.009*,p2 < 0.001*, p3 = 0.144
AST/ALT Ratio H = 18.246 <0.001*
Mean ± SD. 0.94 ± 0.53 1.36 ± 0.54 1.40 ± 0.55 1.10 ± 0.11
pCont. =0.004* 0.045* 0.007*
Sig. bet. grps p1 = 0.001*,p2 = 0.003*, p3 = 0.957
Right lobe liver diameter (cm)/albumin ratio F = 7.855 <0.001*
Mean ± SD. 4.17 ± 0.73 4.94 ± 1.03 4.76 ± 1.36 3.65 ± 0.29
pCont. 0.309 <0.001* 0.002*
Sig. bet. grps p1 = 0.052,p2 = 0.201, p3 = 0.924
H: Kruskal Wallis test, Sig. bet. grps was done using Mann Whitney test.
F: ANOVA test, Sig. bet. grps was done using test (Tukey) for ANOVA.
p: p value for comparing between the four groups.
pCont.: p value for comparing between control and each other periods.
p1: p value for comparing between group I and group II.
p2: p value for comparing between group I and group III.
p3: p value for comparing between group II and group III.
* Statistically significant at p  0.05.
Fig. 1. Comparison between the different studied groups according to serum soluble CD163.
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Fig. 2. ROC curve for Soluble CD163, HOMA IR and Platelets to predict presence of oesophageal varices between (Group II + Group IIIa) vs Group I.
Table 10
Agreement (sensitivity, specificity and accuracy) for different parameters to predict presence of oesophageal varices between (Group II + Group III) vs Group I.
(Group II + Group III)
vs Group I
AUROC p Cut off Sensitivity Specificity PPV NPV
Soluble CD163 0.820* <0.001* >191.71 77.50 75.0 86.1 62.5
HOMA IR 0.763* 0.001* >2.83 67.50 90.0 93.1 58.1
Platelets count 0.734* 0.003* 93 62.50 80.0 86.2 51.6
Soluble CD163 and HOMA IR 0.863* <0.001* 87.50 45.0 76.09 64.29
Soluble CD163 and Platelets 0.845* <0.001* 85.0 65.0 82.93 68.42
Soluble CD163, HOMA IR and Platelets 0.915* <0.001* 90.0 80.0 90.0 80.0
Soluble CD163, platelet count /spleen diameter (mm) and FIB4 0.910* <0.001* 90.0 85.0 92.31 80.95
Soluble CD163, AST ALT ratio and ABRI 0.892* <0.001* 90.0 70.0 85.71 77.78
Soluble CD163, Lok score and PLT 0.882* <0.001* 92.50 75.0 88.10 83.33
Platelet count /spleen diameter (mm) 0.822* <0.001* 643 75.0 85.0 90.9 63.0
FIB4 0.862* <0.001* >4.01 77.50 90.0 93.9 66.7
AST/ALT Ratio 0.785* <0.001* >0.9 77.50 75.0 86.1 62.5
AST to platelets ratio index (APRI) 0.770* <0.001* >1.54 67.50 95.0 96.4 59.4
Lok score 0.735* 0.003* >0.85 87.50 55.0 79.5 68.8
Table 11
Agreement (sensitivity, specificity and accuracy) for soluble CD163 to differentiate small oesophageal varices from large oesophageal varices (Group IIIa vs Group II).
Gp IIIa vs Gp II AUROC p Cut off Sensitivity Specificity PPV NPV
Soluble CD163 0.863* <0.001* >199.19 85.0 90.0 89.5 85.7
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the ROC curve (AUROC) revealed that the cut-off value for HOMA-
IR score of greater than 2.83 was the optimal value for accurate
prediction of EVs with a resulting 67.50% sensitivity, 90% speci-
ficity. The differences between the best cut-off values, sensitivity
and specificity in this study and Cammà et al.26 study may be
attributed to the different ethnic group of the patients, all patients
in this study were non-diabetic and non-obese. Where in Cammà
et al. study 27 patients were diabetic and 11 patients were obese,
and may be due to different genotype of HCV in studied groupswhere genotype 1 predominate Cammà et al. study and genotype
4 mostly predominate this study.
Fib-4 had been examined for the prediction of EV in patients
with cirrhosis, having an AUROC of 0.64 for the prediction of EV
at a cutoff value of 3.5, while for the diagnosis of LEV the AUROC
was 0.63 and the cutoff value 4.3.29 In another study, for predicting
EV, they used a cutoff value of 3.98 and the AUROC was 0.624; for
the diagnosis of LEV they used a cutoff value of 6.75.30 Moreover,
Eman et al.31 proposed a very low cutoff (2.8) for predicting EV
which showed sensitivity 76%, specificity 80%, PPV 92.7% and
Fig. 3. ROC curve for Soluble CD163 to differentiate small oesophageal varices from large oesophageal varices (Group IIIa vs Group II).
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between small EV in group II and large EV in group III and there
was no statistically significant difference. While Sebastiani et al.29
and Stefanescu et al.30 proposed a cutoff value 4.3 and 6.75
respectively.
Lok Score had been considered a very satisfactory predictor of
EV. At a cutoff value of 0.9, the Lok Score had an AUROC of 0.77
for the diagnosis of EV, while for a cutoff value of 1.5, the AUROC
was 0.69 for the prediction of LEV.29 In another prospective study,
the best cutoff value for the diagnosis of LEV was 0.8, with an
AUROC of 0.731 and a NPV of 86.4%.30 While Eman et al.31 pro-
posed a cutoff value of 0.63 for diagnosis of EV. At this cutoff, the
sensitivity was 60%, specificity was 80%, PPV was 78%, NPV was
42.9% and the overall accuracy was 79%. Also, Eman et al.31 pro-
posed a cutoff of 0.72 for the diagnosis of LEV at which sensitivity
was 87.5%, specificity was 55.5% and the overall accuracy was 76%.
AUROC was 0.72. In the current study, we proposed a cutoff 0.85
which showed sensitivity 87.5%, specificity 55%, PPV 79.5% and
NPV 68.8%. However, in this present study Lok Score couldn’t dif-
ferentiate between small EV in group II and large EV in group III
with no statistical significant difference. While Sebastiani et al.29
and Eman et al.31 proposed a cutoff value 1.5 and 0.72 respectively.
Mona et al.32 proposed APRI at a cutoff greater than 1.26 could
predict the presence of EV (AUROC 0.695) with PPV of 81.42% and
APRI at a cutoff greater than 1.47 could predict LEV (AUROC 0.734).
These findings are in agreement with the studies by Castéra et al.33,
Tafarel et al.34, and Adami et al.35 who proposed APRI at a cutoff
1.3, 1.64, and greater than 1.4, respectively, for prediction of EV.
In addition, Sebastiani et al.29 reported APRI at a cutoff of 1.4 for
prediction of EV and at a cutoff of 1.5 for detection of LEV. How-
ever, Stefanescu et al.30 suggested APRI at a cutoff more than
2.201 with AUROC 0.538 for detection of LEV and Galal et al.36 sug-
gested a cutoff greater than 0.16 for detection of EV and LEV. These
different cutoff results indicate the need for further studies in
large-scaled studies.
The AST/ALT ratio has been used to predict cirrhosis, and by nat-
ural extension studies have been performed to assess its usefulness
in predicting oesophageal varices. In a retrospective study by
Neblom et al.37, significantly higher AST/ALT ratio were seen in
patients with varices compared to those without (ratio: 1.8 versus1.0, P < 0.0001). In our study ratio was 1.11 in group I without EV
and 2.47 in group II and 1.93 in group III. Treeptrasertsuk G et al.38
found an AST/ALT ratio >1.12 to be significantly associated with the
presence of varices at initial endoscopy (OR 3.9, P = 0.02 95% CI
1.3–11.8). This cutoff gave a sensitivity of 47.8%, specificity of
87%, PPV 42.3%, and NPV 89.2%, and an AUROC of 0.69. Castéra
et al.33 proposed a cutoff of 1.0 which demonstrated a sensitivity
of 68%, specificity of 89%, PPV 77%, and NPV 83%, with an AUROC
0.83 (0.72–0.94) for predicting the presence of oesophageal
varices. In our study, we proposed a cutoff 0.9 which showed sen-
sitivity 77.5%, specificity 75%, PPV 86.1% and NPV 62.5%. Also, in
this present study AST/ALT ratio couldn’t differentiate between
small EV in group II and large EV in group III and there was no a
statistically significant difference.
Giannini et al.39 introduced the use of the platelet count/spleen
diameter ratio as a tool to predict oesophageal varices. This ratio
links thrombocytopenia to splenomegaly to introduce a variable
that takes into consideration that thrombocytopenia is mainly
due to hypersplenism secondary to portal hypertension. In that
study, when a cut-off value of 909 used, the sensitivity was
100%, and the specificity was 93% this agree with Agha et al.40
Cammà et al.26 studied 104 newly diagnosed patients with Child
A HCV cirrhosis, identified a value of 792 as the best cutoff for
the presence of EVs and ratio greater than 792 Could be useful to
identify patients at low risk of EV. And stated these, different
results are perhaps related to differences in etiology and class of
disease between the two populations as regard Giannini et al.
study39. In one study on Egyptian patients Esmat et al.41 concluded
that a cut-off value of 1326.58 for the platelet count/spleen diam-
eter ratio was used with a resulting 96.34% sensitivity, 83.33%
specificity and 94% accuracy. In another study also in Egyptian
patients Abu El Makarem et al.42 concluded that a cut-off value
of 939.7 for the platelet count/spleen diameter ratio was used with
a resulting 100% sensitivity, 86.3% specificity and 96.5% accuracy.
Monkez et al.43 proposed a cut-off of the platelet count/spleen
diameter ratio 750 for accurate prediction of EVs with a resulting
81% sensitivity, 81% specificity and 81% accuracy. In the current
study, we proposed a cutoff 643 which showed sensitivity 75%,
specificity 85%, PPV 90.9% and NPV 63%. Also, in this present study
platelet count/spleen diameter ratio couldn’t differentiate between
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tistically significant difference. The difference in the cutoff values
between these studies and that of the present work can be
explained by their patient sample that included only cirrhotic
patients, and none of their patients had evidence of bilharziasis,
whereas most of the patients included in the present study had
mixed disease etiology: bilharzial and post viral hepatitis C cirrho-
sis. Both had their insult on the platelets, besides bilharziasis that
specifically produces larger even huge spleen. None of these stud-
ies included these types of patients that are characteristically
prevalent in the Delta region of Egypt. In addition, the absence of
interobserver agreement between the sonographers and endo-
scopists of the different studies which can affect the results. Hence,
it is sure to have our different and specific cutoff that needs further
larger scale studies in Egypt.
Regarding the right liver lobe diameter /serum albumin ratio
Alempijevic et al.44 had counted an original ratio. For the first time
they reported the value of the right liver lobe diameter/serum
albumin concentration in assessment of portal hypertension. They
used serum albumin concentration as a parameter of liver function
in combination with right liver lobe size and used this ratio as a
non-invasive predictor of oesophageal varices with at a cut-off
value of 4.425, the sensitivity was 83.1%, and the specificity was
73.9%. In another study on Egyptian patients Esmat et al.41 con-
cluded that a cut-off value of 4.422 for the right liver lobe diame-
ter/albumin concentration ratio gave sensitivity 91.46%, and the
specificity 77.78%. Monkez et al.43 proposed a cut-off value for
the right liver lobe diameter/albumin concentration ratio 3.5 for
accurate prediction of EVs with a resulting 78.5% sensitivity,
57.1% specificity, and 74% accuracy. On the other hand, El Ray
et al.45 found that right liver lobe diameter/serum albumin had
no role in prediction of EV presence that agrees with our study.
The differences between the best cut-off values, sensitivity, speci-
ficity, and accuracy in these studies may be attributed to the differ-
ent group of patient where all patients in this study were child A, B
and C. In the other studies, the patients were child A, also patients
were had a different ethnic origin. In addition, the differences
between the sonographers of different studies, which can affect
the results. This suggests the need for further multicenter studies
including a large number of patients with different ethnic back-
ground for determining the best cut-off, value for that ratio.
Recent researches has highlighted the important role of liver
macrophages (Kupffer cells) in the fibrotic process.46 Macrophage-
specific markers may, therefore, prove to be useful for the monitor-
ing of fibrosis development like serum soluble CD163.47,48 These
endocytic macrophage surface receptors are shed from activated
macrophages during inflammation.49,50 Rødgaard-Hansen et al.48
was the first to indicate thatmacrophage-related sCD163may serve
as biomarkers for fibrosis. This marker are readily measurable in
serum and reflect monocyte/macrophage activation. In the current
study, soluble CD163 showed a statistically significant difference
between control and liver cirrhosis groups and this agrees with
Ying-Ying et al.51 and Gronaek et al.52When applying ROC curves
of serum soluble CD163 level, it was a significantly good predictors
for presence of oesophageal varices between group I (no EV) and
other both groups II and III (those of EV) with cut off value
>191.71 ng/ml with 77.50% sensitivity and 77.0% specificity. This
agrees with Ying-Ying et al.51 and Waidmann et al.53
An interesting new finding is the ability of the studied marker
soluble CD163 to differentiate between small varices and large
varices with cut off value 199.19 with 85.0 % sensitivity and
90.0% specificity. This is the first study to correlate sCD163 with
grading of EV as noninvasive predictor. No previous studies had
correlated this marker after eradication of EV. However, PeterHolland-fischer et al.14 proposed That normalization of the portal
hypertension by the TIPS procedure did not normalize sCD163,
which remained increased.
After searching the literature, no studies were found to show a
relation between bilharsiasis and sCD163.In this study, No signifi-
cant difference between sCD163 level in group I patients with or
without hepatic schistosomiasis with median sCD163 level
100.60 ng/ml in patients without schistosomiasis and 175.61 ng/
ml in patients with schistosomiasis. Moreover, No significant dif-
ference between sCD163 level in group II patients with or without
hepatic schistosomiasis with median SCD163 level 194.15 ng/ml in
patients without schistosomiasis and 194.76 ng/ml in patients
with schistosomiasis. Also, in group III. We found a model combin-
ing serum Soluble CD163, HOMA IR and Platelets to predict pres-
ence of oesophageal varices had an area under the curve (AUC) of
0.915 with sensitivity and specificity 90% and 80% respectively.
While, ROC curve for Soluble CD163, platelet count /spleen diame-
ter (mm) and FIB4, had sensitivity and specificity 90% and 85%
respectively with AUC 0.910.5. Conclusion
From our results, Serum soluble CD163 is a good noninvasive
predictor for the presence of esophageal varices EVs and it may
be used for grading of EVs. Serum soluble CD163 level does not
change after esophageal varices eradication and it does not be
effected by presence or absence of bilharsiasis. Insulin resistance
measured by HOMA-IR, Fib-4, Lok Score, APRI, AST/ALT ratio and
platelet count/spleen diameter ratio, are good predictors for the
presence of EV but not for grading of esophageal varices. Right liver
lobe diameter/ serum albumin had no role in prediction of EV pres-
ence. Combining of different noninvasive parameters can increase
area under the curve AUC for prediction of EVs. A model combining
serum Soluble CD163, HOMA IR and Platelets to predict presence of
oesophageal varices had the best AUC. Our recommendations are
studying serum soluble CD163 on larger sample size, CD163 and
risk for variceal bleeding and its correlations with different etiolo-
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